晚期膀胱癌的靶向治疗：我们学到了什么？
Targeted therapy in advanced bladder cancer: what have we learned?
作者信息
Jordan Emmet J, Iyer Gopa
机构信息
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
出版信息
Urol Clin North Am. 2015 May;42(2):253-62, ix. doi: 10.1016/j.ucl.2015.01.006. Epub 2015 Mar 12.
Abstract
Despite advances in the treatment of other genitourinary malignancies, no novel therapies have been approved by the US Food and Drug Administration for urothelial carcinoma (UC) in the last 20 years. To date, no clinical trials of targeted agents in UC have led to improvements in survival compared with cytotoxic therapy. This article outlines representative trials of targeted therapies in UC and discusses the significance of genetic preselection in trial design as a method to optimize responses to these agents, thus, hopefully expanding the armamentarium of treatment options against this lethal disease.
摘要
尽管在其他泌尿生殖系统恶性肿瘤的治疗方面取得了进展，但在过去20年里，美国食品药品监督管理局尚未批准任何针对尿路上皮癌（UC）的新疗法。迄今为止，与细胞毒性疗法相比，针对UC的靶向药物临床试验均未带来生存率的改善。本文概述了UC靶向治疗的代表性试验，并讨论了在试验设计中进行基因预选作为优化对这些药物反应的一种方法的重要性，从而有望扩大针对这种致命疾病的治疗选择范围。
相似文献
1
Targeted therapy in advanced bladder cancer: what have we learned?
Urol Clin North Am. 2015 May;42(2):253-62, ix. doi: 10.1016/j.ucl.2015.01.006. Epub 2015 Mar 12.
2
Targeting FGFR in bladder cancer: ready for clinical practice?
Acta Clin Belg. 2020 Feb;75(1):49-56. doi: 10.1080/17843286.2019.1685738. Epub 2019 Oct 31.
3
Novel therapeutic targets in advanced urothelial carcinoma.
Crit Rev Oncol Hematol. 2016 Feb;98:106-15. doi: 10.1016/j.critrevonc.2015.10.021. Epub 2015 Nov 9.
4
A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.
5
Recommendations for the optimal management of early and advanced urothelial carcinoma.
Cancer Treat Rev. 2012 Aug;38(5):431-41. doi: 10.1016/j.ctrv.2011.10.004. Epub 2011 Nov 23.
6
[Molecular Characterisation of Urothelial Bladder Cancer: Will it Improve Patient Care?].
Aktuelle Urol. 2015 May;46(3):227-35. doi: 10.1055/s-0035-1549992. Epub 2015 Jun 12.
7
Molecular and histopathology directed therapy for advanced bladder cancer.
Nat Rev Urol. 2019 Aug;16(8):465-483. doi: 10.1038/s41585-019-0208-0. Epub 2019 Jul 9.
8
Molecular biology and targeted therapies for urothelial carcinoma.
Cancer Treat Rev. 2015 Apr;41(4):341-53. doi: 10.1016/j.ctrv.2015.03.004. Epub 2015 Mar 24.
9
Genomics and Immunomics in the Treatment of Urothelial Carcinoma.
Curr Oncol. 2022 May 12;29(5):3499-3518. doi: 10.3390/curroncol29050283.
10
Emerging Targeted Therapy for Bladder Cancer.
Hematol Oncol Clin North Am. 2021 Jun;35(3):585-596. doi: 10.1016/j.hoc.2021.02.011. Epub 2021 Apr 15.
引用本文的文献
1
N6-methyladenosine-related single-nucleotide polymorphism analyses identify oncogene RNFT2 in bladder cancer.
Cancer Cell Int. 2022 Oct 5;22(1):301. doi: 10.1186/s12935-022-02701-z.
2
Construction of a Co-Expression Network for lncRNAs and mRNAs Related to Urothelial Carcinoma of the Bladder Progression.
Front Oncol. 2022 Feb 25;12:835074. doi: 10.3389/fonc.2022.835074. eCollection 2022.
3
Identification of the circRNA-miRNA-mRNA Regulatory Network in Bladder Cancer by Bioinformatics Analysis.
Int J Genomics. 2021 Nov 16;2021:9935986. doi: 10.1155/2021/9935986. eCollection 2021.
4
LAPTM4B promotes the progression of bladder cancer by stimulating cell proliferation and invasion.
Oncol Lett. 2021 Nov;22(5):765. doi: 10.3892/ol.2021.13026. Epub 2021 Sep 8.
5
Microarray Expression Profiles and Bioinformatics Analyses Reveal Aberrant Circular RNAs Expression in Bladder Cancer.
Onco Targets Ther. 2020 Oct 27;13:10889-10899. doi: 10.2147/OTT.S270747. eCollection 2020.
6
Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF-κB-modulated tumor progression in bladder cancer in vitro and in vivo.
Environ Toxicol. 2019 Jun;34(6):679-688. doi: 10.1002/tox.22734. Epub 2019 Feb 25.
7
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.
Nat Rev Urol. 2018 Feb;15(2):92-111. doi: 10.1038/nrurol.2017.179. Epub 2017 Nov 14.
8
The Rho GTPase signalling pathway in urothelial carcinoma.
Nat Rev Urol. 2018 Feb;15(2):83-91. doi: 10.1038/nrurol.2017.184. Epub 2017 Nov 14.
9
Sleeping beauty: awakening urothelium from its slumber.
Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F732-F743. doi: 10.1152/ajprenal.00337.2016. Epub 2017 Jan 25.
10
Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma.
Mol Oncol. 2016 Nov;10(9):1450-1460. doi: 10.1016/j.molonc.2016.08.003. Epub 2016 Aug 17.
本文引用的文献
1
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
Eur J Cancer. 2014 Dec;50(18):3145-52. doi: 10.1016/j.ejca.2014.10.013. Epub 2014 Oct 30.
2
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
J Clin Oncol. 2014 Nov 10;32(32):3626-33. doi: 10.1200/JCO.2014.56.3809. Epub 2014 Oct 6.
3
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.
Cancer. 2014 Sep 1;120(17):2684-93. doi: 10.1002/cncr.28767. Epub 2014 May 6.
4
Comprehensive molecular characterization of urothelial bladder carcinoma.
Nature. 2014 Mar 20;507(7492):315-22. doi: 10.1038/nature12965. Epub 2014 Jan 29.
5
Cancer statistics, 2014.
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.
6
Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.
Mod Pathol. 2014 May;27(5):758-64. doi: 10.1038/modpathol.2013.201. Epub 2013 Nov 1.
7
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).
BJU Int. 2014 Mar;113(3):429-36. doi: 10.1111/bju.12437.
8
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.
J Clin Oncol. 2013 Sep 1;31(25):3133-40. doi: 10.1200/JCO.2012.46.5740. Epub 2013 Jul 29.
9
Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.
Anticancer Res. 2013 Jun;33(6):2381-90.
10
FGF receptors: cancer biology and therapeutics.
Med Res Rev. 2014 Mar;34(2):280-300. doi: 10.1002/med.21288. Epub 2013 May 21.
Zotero 插件